Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) has insulin-like effects on myocardial glucose uptake which may contribute to its beneficial effects in the setting of myocardial ischemia. Whether these effects are different in the setting of obesity or type 2 diabetes (T2DM) requires investigation. We examined the cardiometabolic actions of GLP-1 (7–36) in lean and obese/T2DM humans, and in lean and obese Ossabaw swine. GLP-1 significantly augmented myocardial glucose uptake under resting conditions in lean humans, but this effect was impaired in T2DM. This observation was confirmed and extended in swine, where GLP-1 effects to augment myocardial glucose uptake during exercise were seen in lean but not in obese swine. GLP-1 did not increase myocardial oxygen consumption or blood flow in humans or in swine. Impaired myocardial responsiveness to GLP-1 in obesity was not associated with any apparent alterations in myocardial or coronary GLP1-R expression. No evidence for GLP-1-mediated activation of cAMP/PKA or AMPK signaling in lean or obese hearts was observed. GLP-1 treatment augmented p38-MAPK activity in lean, but not obese cardiac tissue. Taken together, these data provide novel evidence indicating that the cardiometabolic effects of GLP-1 are attenuated in obesity and T2DM, via mechanisms that may involve impaired p38-MAPK signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 7×
“Previous studies suggest that the myocardial effects of GLP-1 are mediated via activation of two functionally distinct signaling pathways, namely the cAMP/PKA pathway [1, 6, 42] and the p38-MAPK signaling pathway [4, 46].”
InfluentialNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 11×
“And finally, as noted above, although the current observations suggest that differences in myocardial expression of the GLP-1 receptor do not explain the observed differential responses, the available tools for immunologic detection of the GLP-1 receptor are currently being re-evaluated [4, 32, 36], which prevents def…”
InfluentialNikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · cited 3×
“Although vasodilator effects of GLP-1 have been reported in isolated rodent hearts [1, 46] and in conscious canines with pacing-induced dilated cardiomyopathy [29], other studies report no such effects [4, 7, 26, 30].”
Fox, C. S., Pencina, M. J., Wilson, P. W. F., Paynter, N. P., Vasan, R. S., & D’Agostino, R. B. (2008) · Diabetes Care · doi:10.2337/dc08-0025 · Cited by 247 · cited 1×
“Type 2 diabetes (T2DM) and pre-diabetic states of obesity and insulin resistance are associated with augmented cardiovascular risk [10, 19, 37], through mechanisms involving abnormal fuel delivery and utilization, and vascular dysfunction [45].”
BackgroundYan, W., Zhang, H., Liu, P., Wang, H., Liu, J., Gao, C., Liu, Y., Lian, K., Yang, L., Sun, L., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0329-1 · Cited by 169
The Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154
Cited by
Cardiovascular consequences of metabolic syndrome
Tune, J. D., Goodwill, A. G., Sassoon, D. J., & Mather, K. J. (2017) · Translational Research · doi:10.1016/j.trsl.2017.01.001 · Cited by 568
Self-citationCardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
“Studies in dogs demonstrated an increased myocardial glucose uptake during a hyperinsulinemiceuglycemic clamp [46].”
BackgroundSteven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114
Tate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-015-0518-1 · Cited by 96
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43
Metadata
- Authors
- Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., Perry, K. M., Chisholm, R. L., & Tune, J. D.
- Venue
- Basic Research in Cardiology
- Published
- 2013-06-14
- Volume
- 108
- Issue
- 4
- Pages
- 365-365
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- OpenAlex
- W2061642140
- Cited by
- 51
- References
- 12
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1007/s00395-013-0365-x
- The paper
- Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., Perry, K. M., Chisholm, R. L., & Tune, J. D. (2013). Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Research in Cardiology. https://doi.org/10.1007/s00395-013-0365-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.